Back to Search
Start Over
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
- Source :
- Epidemiology and Psychiatric Sciences
- Publication Year :
- 2020
-
Abstract
- In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression. This commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming to draw implications for clinical practice, research and regulatory science.
- Subjects :
- Adult
medicine.medical_specialty
Epidemiology in Clinical Psychopharmacology
Epidemiology
medicine.medical_treatment
Esketamine
Depressive Disorder, Treatment-Resistant
FDA
evidence-based medicine
regulatory policies
treatment-resistant depression
Internal medicine
medicine
Humans
Ketamine
Regulatory science
Infusions, Intravenous
Drug Approval
Depression (differential diagnoses)
Smoke
Depression
United States Food and Drug Administration
business.industry
Public Health, Environmental and Occupational Health
Evidence-based medicine
medicine.disease
Antidepressive Agents
United States
Psychiatry and Mental health
Nasal spray
business
Treatment-resistant depression
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Epidemiology and Psychiatric Sciences
- Accession number :
- edsair.doi.dedup.....f8eb84c7c105fa94b8436d8c2bf961fa